Oncology and Hematology

Episodes 97-112 of 530

Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
Project Oncology®
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
- Paola Marignani, PhD, EMBA
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Project Oncology®
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
- John Cho, MD, PhD, FRCPC
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
Project Oncology®
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
- John Cho, MD, PhD, FRCPC
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
Project Oncology®
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
- Ryan Quigley
Optimizing Outcomes in Endometrial Cancer: From Surgery to Recurrence Management
Optimizing Outcomes in Endometrial Cancer: From Surgery to Recurrence Management
Advances in Women's Health
Optimizing Outcomes in Endometrial Cancer: From Surgery to Recurrence Management
- Ann Klopp, M.D., Ph.D.
Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
Advances in Women's Health
Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
- Ann Klopp, M.D., Ph.D.
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Project Oncology®
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Project Oncology®
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Addressing Psychological Distress in Lung Cancer: The Emerging Role of EMDR Therapy
Addressing Psychological Distress in Lung Cancer: The Emerging Role of EMDR Therapy
Project Oncology®
Addressing Psychological Distress in Lung Cancer: The Emerging Role of EMDR Therapy
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Project Oncology®
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
Project Oncology®
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
- Jennifer Caudle, DO
- Patrick McGill, MD
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
Project Oncology®
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
- Jacob Sands, MD
- Joshua K. Sabari, MD
Durable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
Durable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
Project Oncology®
Durable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
- Jacob Sands, MD
- Sandip Patel, MD
6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
Project Oncology®
6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
- Jacob Sands, MD
- Millie Das, MD
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
CME/CE
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
0.25 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Christophe Le Tourneau, MD, PhD
0.25 credits
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Project Oncology®
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
- Charles Turck, PharmD, BCPS, BCCCP
- Evandro Bezerra, MD